STROBE Statement—checklist of items that should be included in reports of observational studies
Title and abstract
Item
No.
1
Recommendation
(a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what was
Page
No.
Relevant text from manuscript
a 12 month follow-up study
Page 2
found
Introduction
Background/rationale
2
Explain the scientific background and rationale for the investigation being reported
Pages 3-4
Objectives
3
State specific objectives, including any prespecified hypotheses
Page 4
Methods
Study design
4
Present key elements of study design early in the paper
Page 4
This is a longitudinal observational
retrospective study with a 12 months
follow-up
Setting
5
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,
See page 4
follow-up, and data collection
Participants
6
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of
See page 4
participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and methods of case
ascertainment and control selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of
participants
(b) Cohort study—For matched studies, give matching criteria and number of exposed and
unexposed
Case-control study—For matched studies, give matching criteria and the number of controls per
case
Variables
7
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
Page 5
Give diagnostic criteria, if applicable
Data sources/
8*
measurement
Bias
For each variable of interest, give sources of data and details of methods of assessment
Pages 5-6
(measurement). Describe comparability of assessment methods if there is more than one group
9
Describe any efforts to address potential sources of bias
Page 5
1
In order to minimize the impact of
lines 15-17
seasonality on circulating vitamin D
concentrations,
all
participants
underwent fasting blood sampling for
serum
25(OH)vitamin
D
measurement during autumn-winter
period.
Study size
10
Explain how the study size was arrived at
Page 7
At the best of our knowledge, clinical
lines 3-9
remission and response to treatment
by DAS28 after a 12 months followup in relation to vitamin D status at
RA onset have never been studied
before. Therefore, in order to confirm
the statistical power of this study, we
performed a post-hoc sample size
calculation considering a prevalence
of remission in the subgroup with
normal vitamin D status of 68% and
of
16%
in
patients
with
hypovitaminosis D; thus, we obtained
that eleven patients per subgroup
were enough to reach the statistical
significance with a power of 80% (α
error= 0.05, β error= 0.20).
Continued on next page
2
Quantitative
11
variables
Explain how quantitative variables were handled in the analyses. If applicable, describe which
Page 8
groupings were chosen and why
ESR, serum CRP levels, TJCs,
SJCs and DAS28, US synovitis and
p-D score
Statistical
12
methods
(a) Describe all statistical methods, including those used to control for confounding
Pages 6-7
(b) Describe any methods used to examine subgroups and interactions
Pages 6-7
(c) Explain how missing data were addressed
No missing data /lost patients at the
follow-up
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case-control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling
strategy
Results
Participants
13*
(e) Describe any sensitivity analyses
Pages 6-7
(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined
Page 4
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
Data from seventy-six consecutive
patients referring to the Early
Arthritis
Clinic,
Rheumatology
Unit, Sapienza University of Rome,
for recently onset RA between 2010
(b) Give reasons for non-participation at each stage
Page 4
3
and 2012 were initially obtained.
Among the initial seventy-six
patients, thirty-seven subjects were
considered eligible for the study:
fifteen patients were excluded for
treatment with drugs affecting the
bone and mineral metabolism, eight
for multivitamin supplementation,
one for oral contraceptives, three
for treatment with steroids, one for
intestinal malabsorption, two for
chronic kidney failure, five for
diabetes
mellitus,
three
for
metabolic syndrome and one
refused to participate.
(c) Consider use of a flow diagram
Descriptive data
14*
(a) Give characteristics of study participants (eg demographic, clinical, social) and information on
See Tables 1 and 2
exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
For this study we considered only
patients with full information at
baseline and follow-up
(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data
15*
Cohort study—Report numbers of outcome events or summary measures over time
12 month follow-up study
Among our study population 91.7%
patients were responders to RA
treatment (2.7% good and 89%
moderate responders) according to
the EULAR response criteria.
Disease remission (DAS28 <2.6)
was achieved by 48% of patients.
The percentage of responders was
significantly lower in the subgroup
of patients with hypovitaminosis D
compared to subjects with normal
25(OH) vitamin D levels at baseline
(25(OH) vitamin D< 20 ng/ml:
75% responders (0% good, 75%
moderate response) vs 25(OH)
vitamin D>20 ng/ml: 100%
responders (4% good, 96%
moderate response, p<0.001).
Case-control study—Report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results
16
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision
(eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were
included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time
4
Pages 6-7, statistics section
period
Other analyses
17
Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results
18
Summarise key results with reference to study objectives
Pages 6-7 Statistics session
Page 9, lines
In this study we demonstrated that
15-16
the occurrence of hypovitaminosis
D in early RA is predictive of a
reduced response to treatment and
higher disease activity as evaluated
after 12 months follow-up.
Limitations
19
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss
Page 10
One limitation of the present study
both direction and magnitude of any potential bias
lines 22-24
is the small number of patients;
another limit is the short duration
follow-up, as 12 months may not be
enough
to
ascertain
whether
vitamin D status at baseline has
long term effects on RA activity,
particularly referring to structural
damage.
Interpretation
20
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of
Page 11
These
analyses, results from similar studies, and other relevant evidence
Lines 10-12
support to the immunomodulatory
results
provide
further
action of vitamin D in inflammatory
arthritis and suggest a potential
prognostic role of vitamin D status
at diagnosis in RA evolution.
Generalisability
21
Discuss the generalisability (external validity) of the study results
Page 11
These
results
provide
further
lines 10-14
support to the immunomodulatory
action of vitamin D in inflammatory
arthritis and suggest a potential
prognostic role of vitamin D status
5
at diagnosis in RA evolution..
Serum vitamin D measurement and
possibly vitamin D supplementation
should be considered an additional
option in the management of early
RA patients.
Other information
Funding
22
Give the source of funding and the role of the funders for the present study and, if applicable, for the
Page 11
original study on which the present article is based
line 23
This study was supported by a grant
from Sapienza University of Rome.
Continued on next page
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
6